HK Stock Market Move | CHINA IN-TECH (00464) Soars Over 50%, Plans to Discount About 20% of Shares for Sale, Netting Approximately HK$1.03 Billion
Chinese smart technology company (00464) soared more than 50%, as of the time of writing, up 47.32% to 1.65 Hong Kong dollars, with a trading volume of 18.17 million Hong Kong dollars.
CHINA IN-TECH (00464) surged over 50%, as of the time of writing, rising 47.32% to HK$1.65, with a turnover of HK$181.719 million.
On the news front, CHINA IN-TECH announced a plan to issue 117 million shares, representing approximately 15.48% of the enlarged share capital. The issue price is HK$0.9 per share, a discount of approximately 19.64% from the closing price of HK$1.12 on November 6. The net proceeds of approximately HK$102.9 million will be used for business development, repayment of loans, and general working capital.
It is reported that CHINA IN-TECH is mainly engaged in the design, manufacturing, and sales of electronic hairdressing products, as well as providing information technology system platform development services in China. Approximately HK$100 million of the proceeds will be used for business development, repayment of loans, and general working capital. The issuance is carried out in accordance with the general authorization granted by the shareholders' meeting.
Related Articles

SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.
SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


